Bio-Blog
Macrodevices for Cell Therapy I: Advantages and Disadvantages
On average, there are over 2600 clinical trials for cell and gene therapy products on any given day. Yet very few of these products have made it to...
Expanding Market Access to Cell Therapies: Plan Early to Scale Manufacturing Later
Cell and gene therapies are no longer a promise for the future. They are here today. In fields like oncology, pediatrics, and hematology, gene and...
Likarda Student Intern Recognized by BioNexus KC for ‘Graduate Student Best Poster Award and Scholarship’
Congratulations to our Kansas City University student intern, Kennedy Davis! She was recently awarded ‘Graduate Student Best Poster Award and...
Cell Therapies and Hydrogels: What is Crosslinking? | The Choice of a Hydrogel is Only Part of a Cell Therapy’s Success
Hydrogels start out as liquid solutions of individual polymer chains dissolved in an aqueous (water-based) solvent. To transform this liquid...
How Do Delivery Systems Impact Cell Therapy
As medical innovations advance, cells can be used to repair sites of injury or reverse the effects of disease. However, one of the major challenges...
The “Myth” of Homing: Why Do Cells Need A Delivery System?
It is often thought that therapeutic cells make their way from the point of injection to the location they’re needed. However, this is highly...
What is Biocompatibility and Why Does It Matter?
Medical devices have been implanted in human bodies for decades, starting with the first pacemaker implanted in 1958. In fact, it is estimated that...
2022 NULA and Dr. Julius Wayne Dudley Awards Presented to Dr. Francis Karanu
Dr. Francis Karanu, Likarda’s Director of Cell Therapy and Research and Development was named the 2022 recipient of the Newton Universal Legendary...
Likarda and eQcell Announce License Option Agreement
Likarda’s Custom Hydrogel Encapsulant to be Used as Cell Therapy Delivery System to Treat Equine Lameness Cambridge, Massachusetts, February 17,...
Search
Categories
Macrodevices for Cell Therapy I: Advantages and Disadvantages
On average, there are over 2600 clinical trials for cell and gene therapy products on any given...
Expanding Market Access to Cell Therapies: Plan Early to Scale Manufacturing Later
Cell and gene therapies are no longer a promise for the future. They are here today. In fields...
Likarda Student Intern Recognized by BioNexus KC for ‘Graduate Student Best Poster Award and Scholarship’
Congratulations to our Kansas City University student intern, Kennedy Davis! She was recently...